Vertex (VRTX) Enters Into Agreement to Acquire Alpine Immune Sciences (ALPN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
April 10, 2024 4:01 PM EDT- Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies
- Alpines lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 -
- Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway -
- Alpines protein engineering and immunotherapy expertise augments Vertexs toolbox and capabilities -
- Vertex to host investor call today, April 10, at 4:30 pm ET -
BOSTON &... More
